Improvements in hepatic steatosis (measured by magnetic resonance imaging proton density fat fraction), liver injury (measured by serum alanine aminotransferase) and fibrosis (assessed and measured by vibration-controlled transient elastography and enhanced liver fibrosis score) were observed with semaglutide monotherapy, with the combination regimen further improving hepatic steatosis [129]. The gene discussed is GPT; the disease is fatty liver disease.